Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005

References

Disclaimer: This is the fourth report on vaccine preventable disease and vaccination coverage in Australia, and is produced by the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases and the Australian Institute of Health and Welfare on behalf of the Australian Government Department of Health and Ageing published as a supplement to the Communicable Diseases Intelligence journal Volume 31, June 2007.

Page last updated: 20 July 2007

1.         McIntyre P, Amin J, Gidding H, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1993–1998. Commun Dis Intell 2000;24 Suppl:iii–S83.

2.         McIntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell 2002;26 Suppl:iii–S111.

3.         Brotherton J, McIntyre P, Puech M, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002. Commun Dis Intell 2004;28 Suppl 2:i–S116.

4.         Gidding HF, Burgess MA, Kempe AE. A short history of vaccination in Australia. [erratum appears in Med J Aust 2001;174:260]. Med J Aust 2001;174:37–40.

5.         Hull BP, McIntyre PB, Heath TC, Sayer GP. Measuring immunisation coverage in Australia. A review of the Australian Childhood Immunisation Register. Aust Fam Physician 1999;28:55–60.

6.         Australian Government Department of Health and Ageing, Immunise Australia Program. Immunise Australia: Seven Point Plan. Available from: www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/history Accessed on 13 March 2007.

7.         Samaan G, Roche P, Spencer J, National Tuberculosis Advisory Committee for the Communicable Diseases Network. Tuberculosis notifications in Australia, 2002. Commun Dis Intell 2003;27:449–458.

8.         Li J, Roche P, Spencer J, National Tuberculosis Advisory Committee. Tuberculosis notifications in Australia, 2003. Commun Dis Intell 2004;28:464–473.

9.         Roche PW, National Tuberculosis Advisory Committee, Communicable Diseases Network Australia. Tuberculosis notifications in Australia, 2004. Commun Dis Intell 2006;30:93–101.

10.       Public Health Committee, NHMRC. Surveillance case definitions. Canberra: AGPS, 1994.

11.       Communicable Diseases Network Australia. Interim surveillance case definitions for the Australian National Notifiable Diseases Surveillance System. Version 1, 1 January 2004. Available from: www.health.gov.au/internet/main/publishing.nsf/Content/cda_surveil-nndss-dislist.htm/$FILE/casedef.pdf Accessed on 5 December 2006.

12.       Yohannes K, Roche PW, Roberts A, et al. Australia's notifiable diseases status, 2004, annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2006;30:1–79.

13.       Miller M, Roche P, Yohannes K, et al. Australia's notifiable diseases status, 2003, annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005;29:1–61.

14.       Australian Institute of Health and Welfare (AIHW). Australia's health 2006. AIHW Cat. No. AUS-73. Canberra: AIHW, 2006.

15.       Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Commun Dis Intell 2004;28 Suppl 1:S1–S45.

16.       O'Brien ED, Sam GA, Mead C. Methodology for measuring Australia's childhood immunisation coverage. Commun Dis Intell 1998;22:36–37.

17.       Blogg S, Trent M. Doctor's notification of pertussis. N S W Public Health Bull 1995;9:53–54.

18.       Allen CJ, Ferson MJ. Notification of infectious diseases by general practitioners: a quantitative and qualitative study. Med J Aust 2000;172:325–328.

19.       Bonacruz-Kazzi G, McIntyre P, Hanlon M, Menzies R. Diagnostic testing and discharge coding for whooping cough in a children's hospital. J Paediatr Child Health 2003;39:586–590.

20.       Miller M, Roche P, Spencer J, Deeble M. Evaluation of Australia's National Notifiable Disease Surveillance System. Commun Dis Intell 2004;28:311–323.

21.       Australian Institute of Health and Welfare. Australian hospital statistics 2002–2003. AIHW Cat. No. HSE32. (Health Services Series number 22). Canberra: Australian Institute of Health and Welfare, 2004.

22.       Australian Institute of Health and Welfare. Australian hospital statistics 2003–2004. AIHW Cat. No. HSE37. (Health Services Series number 23). Canberra: Australian Institute of Health and Welfare, 2005.

23.       Australian Institute of Health and Welfare. Australian hospital statistics 2004–2005. AIHW Cat. No. HSE41. (Health Services Series number 26). Canberra: Australian Institute of Health and Welfare, 2006.

24.       National Centre for Classification in Health (NCCH). Performance indicators for coding quality (PICQ 2006™). 2006. Available from: www3.fhs.usyd.edu.au/ncch/7.3.1.htm Accessed on 12 March 2007.

25.       McKenzie K, Walker S, Dixon-Lee C, Dear G, Moran-Fuke J. Clinical coding internationally: a comparison of the coding workforce in Australia, America, Canada and England. Presentation to the 14th International Federation of Health Records Congress, Washington, October 2004. Available from: eprints.qut.edu.au/archive/00000575/01/mckenzie_coding.PDF Accessed on 23 March 2006.

26.       Perry C, Harrison R. The Australian Coding Standards Advisory Committee. Health Inf Manag 2004;32:26–30.

27.       Bramley M. A framework for evaluating health classifications. Health Inf Manag 2005;34:71–83.

28.       O'Malley KJ, Cook KF, Price MD, et al. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40:1620–1639.

29.       MacIntyre CR, Ackland MJ, Chandraraj EJ, Pilla JE. Accuracy of ICD-9-CM codes in hospital morbidity data, Victoria: implications for public health research. Aust N Z J Public Health 1997;21:477–482.

Top of page

30.       Wood N, Menzies R, McIntyre P. Epiglottitis in Sydney before and after the introduction of vaccination against Haemophilus influenzae type b disease. Intern Med J 2005;35:530–535.

31.       Australian Institute of Health and Welfare. Mortality over the twentieth century in Australia: trends and patterns in major causes of death. AIHW Cat. No. PHE73. (Mortality Surveillance Series number 4). Canberra: Australian Institute of Health and Welfare, 2005.

32.       The Royal College of Pathologists of Australasia Autopsy Working Party. The decline of the hospital autopsy: a safety and quality issue for healthcare in Australia. Med J Aust 2004;180:281–285.

33.       Mant J, Wilson S, Parry J, et al. Clinicians didn't reliably distinguish between different causes of cardiac death using case histories. J Clin Epidemiol 2006;59:862–867.

34.       Ravakhah K. Death certificates are not reliable: revivification of the autopsy. South Med J 2006;99:728–733.

35.       Nashelsky MB, Lawrence CH. Accuracy of cause of death determination without forensic autopsy examination. Am J Forensic Med Pathol 2003;24:313–319.

36.       Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. JAMA 2003;289:2849–2856.

37.       Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology 2005;47:551–559.

38.       Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child 2002;86:336–338.

39.       Sutter RW, Cochi SL, Brink EW, Sirotkin BI. Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979–1984. Am J Epidemiol 1990;131:132–142.

40.       Korda RJ, Butler JR. Trends in pneumonia rates explained by changes in coding practices. Intern Med J 2005;35:138–139.

41.       Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Immunisation coverage in Australia corrected for under-reporting to the Australian Childhood Immunisation Register. Aust N Z J Public Health 2003;27:533–538.

42.       Lister S, McIntyre PB, Burgess MA, O'Brien ED. Immunisation coverage in Australian children: a systematic review 1990–1998. Commun Dis Intell 1999;23:145–170.

43.       Plotkin SA, Orenstein WA, eds. Vaccines. 4th edn. Philadelphia: WB Saunders, 2004.

44.       Heymann DL, ed. Control of communicable diseases manual. 18th edn. Washington, D.C.: American Public Health Association, 2004.

45.       Hatanaka A, Tsunoda A, Okamoto M, et al. Corynebacterium ulcerans diphtheria in Japan. Emerg Infect Dis 2003;9:752–753.

46.       DeWinter LM, Bernard KA, Romney MG. Human clinical isolates of Corynebacterium diphtheriae and Corynebacterium ulcerans collected in Canada from 1999 to 2003 but not fitting reporting criteria for cases of diphtheria. J Clin Microbiol 2005;43:3447–3449.

47.       Centre for Disease Control Northern Territory. Guidelines for the control of diphtheria in the Northern Territory. Darwin: Northern Territory Government Department of Health and Community Services, 2004. Available from: www.nt.gov.au/health/cdc/treatment_protocol/dipthteria.pdf Accessed on 1 December 2006.

48.       World Health Organization (WHO). Diphtheria reported cases. WHO, 2006. Available from: www.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidencedip.htm Accessed on 3 December 2006.

49.       Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis 1998;4:539–550.

50.       World Health Organization (WHO). Diphtheria in the WHO European Region. WHO, 2006. www.euro.who.int/vaccine/20030724_3 Accessed on 3 December 2006.

51.       Wren MW, Shetty N. Infections with Corynebacterium diphtheriae: six years' experience at an inner London teaching hospital. Br J Biomed Sci 2005;62:1–4.

52.       Romney MG, Roscoe DL, Bernard K, et al. Emergence of an invasive clone of nontoxigenic Corynebacterium diphtheriae in the urban poor population of Vancouver, Canada. J Clin Microbiol 2006;44:1625–1629.

53.       de Benoist AC, White JM, Efstratiou A, et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis 2004;10:511–513.

54.       Sing A, Heesemann J. Imported cutaneous diphtheria, Germany, 1997–2003. Emerg Infect Dis 2005;11:343–344.

55.       Lumio J, Suomalainen P, Ölander RM, Saxén H, Salo E. Fatal case of diphtheria in an unvaccinated infant in Finland. Pediatr Infect Dis J 2003;22:844–846.

56.       Centers for Disease Control and Prevention. Fatal respiratory diphtheria in a U.S. traveler to Haiti-Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep 2004;52:1285–1286.

57.       Booy R, Haworth EA, Ali KA, Chapel HM, Moxon ER. Immunogenicity of routine vaccination against diphtheria, tetanus, and Haemophilus influenzae type b in Asian infants born in the United Kingdom. Arch Dis Child 2005;90:589–591.

58.       Gidding HF, Backhouse JL, Burgess MA, Gilbert GL. Immunity to diphtheria and tetanus in Australia: a national serosurvey. Med J Aust 2005;183:301–304.

59.       McIntyre PB, Leeder SR, Irwig LM. Invasive Haemophilus influenzae type b disease in Sydney children 1985–1987: a population-based study. Med J Aust 1991;154:832–837.

Top of page

60.       Gilbert GL, Clements DA, Broughton SJ. Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987. Pediatr Infect Dis J 1990;9:252–257.

61.       Hanna J. The epidemiology and prevention of Haemophilus influenzae infections in Australian aboriginal children. J Paediatr Child Health 1992;28:354–361.

62.       Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302–317.

63.       Bisgard KM, Kao A, Leake J, et al. Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998;4:229–237.

64.       McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521–1523.

65.       Conaty S, Bird P, Bell G, et al. Hepatitis A in New South Wales, Australia from consumption of oysters: the first reported outbreak. Epidemiol Infect 2000;124:121–130.

66.       Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Epidemiol Infect 1998;121:631–636.

67.       Hanna JN, Warnock TH, Shepherd RW, Selvey LA. Fulminant hepatitis A in indigenous children in north Queensland. Med J Aust 2000;172:19–21.

68.       Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med J Aust 2001;174:338–341.

69.       Gilroy NM, Tribe IG, Passaris I, Hall R, Beers MY. Hepatitis A in injecting drug users: a national problem. Med J Aust 2000;172:142–143.

70.       Munnoch SA, Ashbolt RH, Coleman DJ, et al. A multi-jurisdictional outbreak of hepatitis A related to a youth camp—implications for catering operations and mass gatherings. Commun Dis Intell 2004;28:521–527.

71.       Schultz R. Hepatitis A outbreak in Central Australia. The Northern Territory Disease Control Bulletin 2005;12:4–7.

72.       Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States – implications for vaccination strategies. J Infect Dis 1998;178:1579–1584.

73.       Brown GR, Persley K. Hepatitis A epidemic in the elderly. South Med J 2002;95:826–833.

74.       Centers for Disease Control and Prevention. Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002–2004. MMWR Morb Mortal Wkly Rep 2005;54:453–456.

75.       Yohannes K, Roche P, Blumer C, et al. Australia's notifiable diseases status, 2002: Annual report of the National Notifiable Diseases Surveillance System. [erratum appears in Commun Dis Intell 2006;30:221]. Commun Dis Intell 2004;28:6–68.

76.       National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003.

77.       Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Commun Dis Intell 2004;28:127–159.

78.       Adams L, Johnson G. Hepatitis A virus infection, immunisation and the Kimberley [letter]. Kimberley Public Health Bulletin 2003;May:13.

79.       Bowden FJ, Currie BJ, Miller NC, Locarnini SA, Krause VL. Should aboriginals in the "top end" of the Northern Territory be vaccinated against hepatitis A? Med J Aust 1994;161:372–373.

80.       D'Argenio P, Adamo B, Cirrincione R, Gallo G. The role of vaccine in controlling hepatitis A epidemics. Vaccine 2003;21:2246–2249.

81.       Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 2004;181:482–485.

82.       Government provides free hepatitis A vaccine to Indigenous children. Media release. Minister for Health and Ageing. 28 June 2005. Available from: www.health.gov.au/internet/ministers/publishing.nsf/content/health-mediarel-yr2005-ta-abb079.htm/$FILE/abb079.pdf Accessed on July 2006.

83.       Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR–7):1–23.

84.       Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review. Med J Aust 1996;165:322–326.

85.       Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: chronic viral hepatitis. BMJ 2001;322:219–221.

86.       O'Sullivan BG, Gidding HF, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004;28:212–216.

87.       Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978–1997: increasing incidence and mortality. Med J Aust 2000;173:403–405.

88.       Williams A. Reduction in the hepatitis B related burden of disease—measuring the success of universal immunisation programs. Commun Dis Intell 2002;26:458–460.

89.       Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938–945.

Top of page

90.       Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis, Hepatitis C Sub-Committee. Hepatitis C virus projections working group: estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney: National Centre in HIV Epidemiology and Clinical Research, 2006. Available from: www.health.gov.au/internet/main/publishing.nsf/Content/phd-hepc-estimates-project-06-l Accessed on April 2007.

91.       Skinner R, Nolan T. Adolescent hepatitis B immunisation – should it be the law? Aust N Z J Public Health 2001;25:230–233.

92.       Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349–352.

93.       Huang KY, Lin SR. Nationwide vaccination: a success story in Taiwan. Vaccine 2000;18 Suppl 1:S35–S38.

94.       Moloney M. Acute hepatitis B in Victoria 1997–2003. Victorian Infectious Diseases Bulletin 2004;7:58–59.

95.       Condon JR, Barnes T, Cunningham J, Armstrong BK. Long-term trends in cancer mortality for Indigenous Australians in the Northern Territory. Med J Aust 2004;180:504–507.

96.       Roche P, Spencer J, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2001. Commun Dis Intell 2002;26:204–213.

97.       Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States – an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163:181–187.

98.       Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322–1332.

99.       Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232–239.

100.     Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ 2004;329:660.

101.     Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–186.

102.     Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998;178:53–60.

103.     Lister S, McIntyre P, Menzies R. The epidemiology of respiratory syncytial virus infections in New South Wales children, 1992–1997. N S W Public Health Bull 2000;11:119–123.

104.     Birch CJ, Clothier HJ, Seccull A, et al. Human coronavirus OC43 causes influenza-like illness in residents and staff of aged-care facilities in Melbourne, Australia. Epidemiol Infect 2005;133:273–277.

105.     Druce J, Tran T, Kelly H, et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002–2003. J Med Virol 2005;75:122–129.

106.     Turner J, Tran T, Birch C, Kelly H. Higher than normal seasonal influenza activity in Victoria, 2003. Commun Dis Intell 2004;28:175–180.

107.     Yohannes K, Roche P, Hampson A, Miller M, Spencer J. Annual report of the National Influenza Surveillance Scheme, 2003. Commun Dis Intell 2004;28:160–168.

108.     Li J, Hampson A, Roche PW, Yohannes K, Spencer JD. Annual report of the National Influenza Surveillance Scheme, 2004. Commun Dis Intell 2005;29:125–136.

109.     Firestone SM, Barr IG, Roche PW, Walker JC. Annual report of the National Influenza Surveillance Scheme, 2005. Commun Dis Intell 2006;30:189–200.

110.     Australian Institute of Health and Welfare. 2003 Influenza vaccine survey: summary results. AIHW Cat. No. PHE 51. Canberra: Australian Institute of Health and Welfare, Australian Government Department of Health and Ageing, 2004. Available from: www.aihw.gov.au/publications/phe/ivs03sr/ivs03sr.pdf Accessed on 15 December 2006.

111.     Australian Institute of Health and Welfare. 2004 Adult vaccination survey: summary results. AIHW Cat. No. PHE 56. Canberra: Australian Institute of Health and Welfare, Australian Government Department of Health and Ageing, 2005. Available from: www.aihw.gov.au/publications/phe/avssr04/avssr04.pdf Accessed on 15 December 2006.

112.     Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006;333:1241.

113.     Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule – United States, January–June 2004. MMWR Morb Mortal Wkly Rep 2004;53:Q1–Q4.

114.     American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics 2004;113:1441–1447.

115.     Centers for Disease Control and Prevention. Update: influenza activity – United States, 2003–04 season. MMWR Morb Mortal Wkly Rep 2004;53:284–287.

116.     Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225–231.

117.     Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). [erratum appears in MMWR Morb Mortal Wkly Rep 2006;55:800]. MMWR Recomm Rep 2006;55(RR–10):1–42.

118.     Beard F, McIntyre P, Gidding H, Watson M. Influenza related hospitalisations in Sydney, New South Wales, Australia. Arch Dis Child 2006;91:20–25.

119.     Milne BG, Williams S, May ML, et al. Influenza A associated morbidity and mortality in a Paediatric Intensive Care Unit. Commun Dis Intell 2004;28:504–509.

Top of page

120.     Isaacs D. Should all Australian children be vaccinated against influenza? Questions of cost-effectiveness, vaccine efficacy and feasibility are yet to be answered. Med J Aust 2005;182:553–554.

121.     Olsen B, Munster VJ, Wallensten A, et al. Global patterns of influenza a virus in wild birds. Science 2006;312:384–388.

122.     Avian influenza frequently asked questions. Wkly Epidemiol Rec 2004;79:77–83.

123.     Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003;302:1519–1522.

124.     Fedson DS. Vaccination for pandemic influenza: a six point agenda for interpandemic years. Pediatr Infect Dis J 2004;23 Suppl 1:S74–S77.

125.     World Health Organization. Guidelines for the use of seasonal influenza vaccine in humans at risk of H5N1 infection. 2004. Available from: www.who.int/csr/disease/avian_influenza/guidelines/seasonal_vaccine/en/ Accessed on 15 December 2006.

126.     Counahan M, Tobin S, Andrews R, et al. Measles–get vaccinated! Victorian Infectious Diseases Bulletin 2003;6:33–34.

127.     Centers for Disease Control and Prevention. Progress toward measles elimination-region of the Americas, 2002–2003. MMWR Morb Mortal Wkly Rep 2004;53:304–306.

128.     World Health Organization, United Nations Children's Fund. Measles. Mortality reduction and regional elimination. Strategic plan 2001–2005. (WHO/V&B/01.13 Rev. 1). Geneva: WHO, 2001. Available from: www.who.int/vaccines-documents/DocsPDF01/www573.pdf Accessed on 1 December 2006.

129.     Turnbull FM, Burgess MA, McIntyre PB, et al. The Australian Measles Control Campaign, 1998. Bull World Health Organ 2001;79:882–888.

130.     Gidding H. Monitoring measles control in Australia: the national serosurveillance program. The Broad Street Pump [Centre for Infectious Diseases and Microbiology – Public Health, Newsletter] 2006;(8): Available from: www.cidmpublichealth.info/cidmphnews.htm Accessed on 12 April 2007.

131.     Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16–17 March 2000. J Infect Dis 2004;189 Suppl 1:S43–S47.

132.     Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004;189 Suppl 1:S1–S3.

133.     World Health Organization Regional Office for the Western Pacific. Measles elimination. Meeting papers of the Regional Committee 56th session, Noumea, New Caledonia, 19–23 September 2005. WPR/RC56/11. 14 July 2005. Available from: www.wpro.who.int/NR/rdonlyres/8A5EF40A-DDC6-4CB2-9CBE-86A589DDF80D/0/15_measles.pdf Accessed on 5 October 2006.

134.     MacIntyre CR, Hull B, Burgess M, Gay N. Measles control in NSW divisions of general practice. N S W Public Health Bull 2003;14:13–17.

135.     Chibo D, Riddell M, Catton M, et al. Studies of measles viruses circulating in Australia between 1999 and 2001 reveals a new genotype. Virus Res 2003;91:213–221.

136.     Cohen NJ. Introduction of the National Meningococcal C Vaccination Program. Commun Dis Intell 2003;27:161–162.

137.     Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia [editorial]. Med J Aust 2007;186:108–109.

138.     NSW Health. Extended funding for Meningococcal C vaccine. 2006. Available from: www.health.nsw.gov.au/living/immunisation/immunise_prog/menvaccine.html Accessed on 12 April 2007.

139.     Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2005. Commun Dis Intell 2006;30:211–221.

140.     Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. The Lancet Infectious Diseases 2006;6:616–617.

141.     de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van DerEnde A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006;25:79–80.

142.     Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization – international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006;24:5093–5107.

143.     Thornton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006;24:1395–1400. PM:16242221

144.     Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16–24 months. Pediatr Infect Dis J 2007;26:345–350. PM:17414400

145.     Gidding HF, Wood J, MacIntyre CR, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007; In press.

146.     Centers for Disease Control and Prevention. Mumps epidemic – United Kingdom, 2004–2005. MMWR Morb Mortal Wkly Rep 2006;55:173–175.

147.     Office for National Statistics. Mid-2005 population estimates: England and Wales; estimated resident population by single year of age and sex. Available from: www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D9389.xls Accessed on 3 November 2006.

148.     Centers for Disease Control and Prevention. Update: multistate outbreak of mumps – United States, January 1–May 2, 2006. MMWR Morb Mortal Wkly Rep 2006;55:559–563.

149.     Torvaldsen S, McIntyre P. Do variations in pertussis notifications reflect incidence or surveillance practices? A comparison of infant notification rates and hospitalisation data in NSW. N S W Public Health Bull 2003;14:81–84.

Top of page

150.     Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 2003;22:956–959.

151.     Brotherton J, McAnulty J. A pertussis epidemic in NSW: how epidemiology reflects vaccination policy. N S W Public Health Bull 2003;14:77–81.

152.     Rank C. Epidemiologic impact and vaccine effectiveness following an adolescent pertussis vaccination program in New South Wales. Masters of International Public Health thesis. University of Sydney. 2006.

153.     Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004;23:985–989.

154.     Elliott E, McIntyre P, Ridley G, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246–252.

155.     Schellekens J, Wirsing von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005;24 Suppl 5:S19–S24.

156.     Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005.

157.     Krause VL, Reid SJ, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. Med J Aust 2000;173 Suppl:S27–S31.

158.     Mak DB. Invasive pneumococcal disease in the Kimberley, 1995–2001. Aust J Rural Health 2004;12:237–240.

159.     Torzillo PJ, Hanna J, Morey F, et al. Invasive pneumococcal disease in central Australia. Med J Aust 1995;162:182–186.

160.     Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001. Commun Dis Intell 2002;26:505–519.

161.     Roche P, Krause V, Andrews R, et al. Invasive pneumococcal disease in Australia, 2002. Commun Dis Intell 2003;27:466–477.

162.     Roche P, Krause V, Bartlett M, et al. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28:441–454.

163.     Roche P, Krause V, Bartlett M, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30:80–92.

164.     Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005;54:893–897.

165.     Madsen KM, Schonheyder HC, Kistensen B, Nielsen GL, Sorensen HT. Can hospital discharge diagnosis be used for surveillance of bacteraemia? A data quality study of a Danish hospital discharge registry. Infect Control Hosp Epidemiol 1998;19:175–180.

166.     Straetemans M, Sanders EA, Veenhoven RH, et al. Pneumococcal vaccines for preventing otitis media. Cochrane Database Syst Rev 2004;(1):CD001480. DOI: 10.1002/14651858.CD001480.pub2.

167.     Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine–type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Cochrane Database Syst Rev 2004;(4):CD004977. DOI: 10.1002/14651858.CD004977.

168.     Dear KB, Andrews RR, Holden J, Tatham DP. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2004;(4):CD000422. DOI: 10.1002/14651858.CD000422.

169.     Benin AL, O'Brien KL, Watt JP, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis 2003;188:81–89.

170.     Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland, 1999–2004. Med J Aust 2006;184:118–121.

171.     Krause V, Cook H, Selvey CE. Impact of 7vPCV and 23vPPV booster in eligible children in the Northern Territory of Australia: impressive, but not the total answer. Poster presented at 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD5), Alice Springs, Central Australia, April 2006.

172.     Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease in Victoria, Australia. Vaccine 2004;23:132–138.

173.     Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep 2006;55:1093–1097.

174.     Commonwealth Department of Health and Aged Care. National documentation for certification of poliomyelitis eradication in Australia. Canberra: Commonwealth of Australia, 2000.

175.     World Health Organization. Major milestone reached in global polio eradication: Western Pacific Region is certified polio-free. Commun Dis Intell 2000;24:304.

176.     Sullivan AA, Boyle RS, Whitby RM. Vaccine-associated paralytic poliomyelitis. Med J Aust 1995;163:423–424.

177.     Catton M, Brussen KA, Kennett M. Vaccine-associated paralytic poliomyelitis. Med J Aust 1996;164:255–256.

178.     Stambos V, Brussen KA, Thorley BR. Annual report of the Australian National Poliovirus Reference Laboratory, 2004. Commun Dis Intell 2005;29:263–268.

179.     Brussen KA, Roberts J, Ibrahim A, Stambos V, Thorley BR. Annual report of the Australian National Poliovirus Reference Laboratory 2005. Commun Dis Intell 2006;30:334–340.

Top of page

180.     Kelly H, Brussen KA, Lawrence A, et al. Polioviruses and other enteroviruses isolated from faecal samples of patients with acute flaccid paralysis in Australia, 1996–2004. J Paediatr Child Health 2006;42:370–376.

181.     Zurynski Y, Cronin PA, Elliott EJ. Communicable and vaccine-preventable conditions under surveillance by the APSU: 2005 update. Commun Dis Intell 2006;30:341–344.

182.     Morris AM, Elliott EJ, D'Souza RM, et al. Acute flaccid paralysis in Australian children. J Paediatr Child Health 2003;39:22–26.

183.     Whitfield K, Kelly H. Notification of patients with acute flaccid paralysis since certification of Australia as polio-free. J Paediatr Child Health 2004;40:466–469.

184.     Whitfield K, Kelly H. Using the two-source capture-recapture method to estimate the incidence of acute flaccid paralysis in Victoria, Australia. Bull World Health Organ 2002;80:846–851.

185.     Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation – 21 countries, 2002–2005. MMWR Morb Mortal Wkly Rep 2006;55:145–150.

186.     Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication – India, January 2005–June 2006. MMWR Morb Mortal Wkly Rep 2006;55:772–776.

187.     Global polio eradication initiative website. Available from: www.polioeradication.org Accessed on 29 September 2006.

188.     World Health Organization. Global polio eradication initiative strategic plan 2004–2008. 2003. Available from: www.polioeradication.org/content/publications/2004stratplan.pdf Accessed on 9 March 2007.

189.     Wood N, Thorley B. Towards global poliomyelitis eradication: The successes and challenges for a developed country. J Paediatr Child Health 2003;39:647–650.

190.     Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis 2006;194:545–551.

191.     Dowdle W, Kew O. Vaccine-derived polioviruses: is it time to stop using the word "rare"? J Infect Dis 2006;194:539–541.

192.     Durrheim DN, Massey IP, Kelly H. Re-emerging poliomyelitis—is Australia's surveillance adequate? Commun Dis Intell 2006;30:275–277.

193.     Thorley BR, Brussen KA, Elliott EJ, Kelly HA. Vigilance is required for Australia to remain polio free [letter]. Med J Aust 2006;184:474–475.

194.     Harris RJ, Storm PA, Lloyd A, Arens M, Marmion BP. Long-term persistence of Coxiella burnetii in the host after primary Q fever. Epidemiol Infect 2000;124:543–549.

195.     Parker NR, Barralet JH, Bell AM. Q fever. Lancet 2006;367:679–688.

196.     Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after acute Q fever. Lancet 1996;347:977–978.

197.     Ayres JG, Flint N, Smith E.G, et al. Post-infection fatigue syndrome following Q fever. QJM: monthly journal of the Association of Physicians 1998;91:105–123.

198.     Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999;12:518–553.

199.     Marmion BP, Ormsbee RA, Kyrkou M, et al. Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs. Epidemiol Infect 1990;104:275–287.

200.     Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985–1990. Med J Aust 1994;160:704–708.

201.     Shapiro RA, Siskind V, Schofield FD, et al. A randomized, controlled, double-blind, cross-over, clinical trial of Q fever vaccine in selected Queensland abattoirs. Epidemiol Infect 1990;104:267–273.

202.     Garner MG, Longbottom HM, Cannon RM, Plant AJ. A review of Q fever in Australia 1991–1994. Aust N Z J Public Health 1997;21:722–730.

203.     Australian Government Department of Health and Ageing. Immunisation programs and initiatives. Q fever management program. 2006. Available from: www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/q-fever-man Accessed on 23 March 2006.

204.     Massey P, Taylor K. Q fever cluster in a shearing team. N S W Public Health Bull 2004;15:223–224.

205.     Comments on notifications 1 January to 31 March 2004 and 2003. Q fever. The Northern Territory Disease Control Bulletin 2004;11:49.

206.     Comments on disease notifications with significant increases. Q fever. The Northern Territory Disease Control Bulletin 2005;12:36.

207.     Marmion B, Harris R, Storm P, et al. Q Fever Research Group (QRG), Adelaide: activities – exit summary 1980–2004. Ann N Y Acad Sci 2005;1063:181–186.

208.     Public Health Group. Vu T, Counahan M, Morgan M, Lester R, eds. Surveillance of notifiable infectious diseases in Victoria, 2003. Melbourne: Communicable Diseases Section, Rural and Regional Health and Aged Care Services, Victorian Department of Human Services, 2005. Available from: www.health.vic.gov.au/ideas/downloads/annual_rpts/snid2003_complete.pdf Accessed on 15 December 2006.

209.     Public Health Branch. Fielding J, ed. Surveillance of notifiable infectious diseases in Victoria, 2004. Melbourne: Communicable Diseases Section, Rural and Regional Health and Aged Care Services, Victorian Department of Human Services, 2006. Available from: www.health.vic.gov.au/ideas/downloads/annual_rpts/snid2004_complete.pdf Accessed on 15 December 2006.

Top of page

210.     Lin M, Delpech V, McAnulty J, Campbell-Lloyd S. Epireview: notifications of Q fever in New South Wales, 1991–2000. N S W Public Health Bull 2001;12:172–175.

211.     Milazzo A, Featherstone KB, Hall RG. Q fever vaccine uptake in South Australian meat processors prior to the introduction of the National Q Fever Management Program. Commun Dis Intell 2005;29:400–406.

212.     Greenslade E, Beasley R, Jennings L, Woodward A, Weinstein P. Has Coxiella burnetii (Q fever) been introduced into New Zealand? Emerg Infect Dis 2003;9:138–140.

213.     Hilbink F, Penrose M, Kovacova E, Kazar J. Q fever is absent from New Zealand. Int J Epidemiol 1993;22:945–949.

214.     Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. A pedagogical farm as a source of Q fever in a French city. Eur J Epidemiol 2005;20:957–961.

215.     van Woerden HC, Mason BW, Nehaul LK, et al. Q fever outbreak in industrial setting. Emerg Infect Dis 2004;10:1282–1289.

216.     Porten K, Rissland J, Tigges A, et al. A super-spreading ewe infects hundreds with Q fever at a farmers' market in Germany. BMC Infectious Diseases 2006;6:147. Available from: www.biomedcentral.com/1471-2334/6/147 Accessed on 23 October 2006.

217.     McQuiston JH, Holman RC, McCall CL, et al. National surveillance and the epidemiology of human Q fever in the United States, 1978–2004. Am J Trop Med Hyg 2006;75:36–40.

218.     Health Protection Agency. Q fever. Background information. 2006. Available from: www.hpa.org.uk/infections/topics_az/zoonoses/q_fever/gen_info.htm Accessed on 23 October 2006.

219.     Clark HF, Offit PA, Glass RI, Ward RL. Rotavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Pennsylvania: W.B. Saunders Company, 2004.

220.     Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022–1028.

221.     Newall AT, MacIntyre R, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. J Paediatr Child Health 2006;42:521–527.

222.     Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR–12):1–13.

223.     Kirkwood CD, Bogdanovic-Sakran N, Cannan D, Bishop RF, Barnes GL. National Rotavirus Surveillance Program annual report, 2004–05. Commun Dis Intell 2006;30:133–136.

224.     Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23–33.

225.     Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11–22.

226.     Armstrong P. Rotaviral gastroenteritis in the NT: a description of the epidemiology 1995–2001 and future directions for research. The Northern Territory Disease Control Bulletin 2001;8(3):1–5. Available from: www.nt.gov.au/health/cdc/bulletin/sept_2001.pdf Accessed on November 2006.

227.     Blumer C, Roche P, Kirkwood C, Bishop R, Barnes G. Surveillance of viral pathogens in Australia: rotavirus. Commun Dis Intell 2003;27:496–503.

228.     Carlin JB, Chondros P, Masendycz P, et al. Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993–1996. Med J Aust 1998;169:252–256.

229.     NSW Health Department. Managing young children and infants with gastroenteritis: clinical practice guidelines. Sydney: NSW Health Department, 2002.

230.     Riordan FA, Quigley T. Estimating hospital admissions due to rotavirus gastroenteritis from hospital episode statistics. J Infect 2004;49:13–16.

231.     Hsu VP, Staat MA, Roberts N, et al. Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalizations in children. Pediatrics 2005;115:78–82.

232.     Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Aust N Z J Public Health 2006;30:416–421.

233.     Bishop RF, Masendycz PJ, Bugg HC, Carlin JB, Barnes GL. Epidemiological patterns of rotaviruses causing severe gastroenteritis in young children throughout Australia from 1993 to 1996. J Clin Microbiol 2001;39:1085–1091.

234.     Kirkwood C, Bogdanovic-Sakran N, Clark R, et al. Report of the Australian Rotavirus Surveillance Program, 2001/2002. Commun Dis Intell 2002;26:537–540.

235.     Kirkwood CD, Bogdanovic-Sakran N, Clark R, Bishop RF, Graeme LB. Report of the Australian rotavirus surveillance program 2002–03. Commun Dis Intell 2003;27:492–495.

236.     Kirkwood C, Bogdanovic-Sakran N, Ruth B, Barnes G. Report of the Australian Rotavirus Surveillance Program 2003–2004. Commun Dis Intell 2004;28:481–485.

237.     Kirkwood C, Bogdanovic-Sakran N, Barnes G, Bishop R. Rotavirus serotype G9P[8] and acute gastroenteritis outbreak in children, Northern Australia. Emerg Infect Dis 2004;10:1593–1600.

238.     Schultz R. Rotavirus gastroenteritis in the Northern Territory, 1995–2004. Med J Aust 2006;185:354–356.

239.     Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006;25 Suppl 1:S7–S11.

Top of page

240.     Ringenbergs ML, Davidson GP, Spence J, Morris S. Prospective study of nosocomial rotavirus infection in a paediatric hospital. Aust Paediatr J 1989;25:156–160.

241.     Snelling T, Cripps T, Macartney K, et al. Nosocomial rotavirus infection in an Australian children's hospital [letter]. J Paediatr Child Health 2007;43:327.

242.     World Health Organization (WHO). Rubella vaccines WHO position paper. Wkly Epidemiol Rec 2000;75:161–169.

243.     Elliot E, Cronin P, Rose D, Zurynski Y, eds. Australian Paediatric Surveillance Unit surveillance report 2002–2003. Sydney: Australian Paediatric Surveillance Unit, 2005. Available from: www.apsu.org.au/publications%202_files/APSU_report.pdf Accessed on April 2007.

244.     Elliot E, Cronin P, Zurynski Y, eds. Australian Paediatric Surveillance Unit annual report 2004. Sydney: Australian Paediatric Surveillance Unit, 2005. Available from: www.apsu.org.au/publications%202_files/FINAL%20REPORT%202004.pdf Accessed on April 2007.

245.     Kelly H, Worth L, Karapanagiotidis T, Riddell M. Interruption of rubella virus transmission in Australia may require vaccination of adult males: evidence from a Victorian sero-survey. Commun Dis Intell 2004;28:69–73.

246.     Gidding HF, Young M, Pugh R, Burgess M. Rubella in Australia: can we explain two recent cases of congenital rubella syndrome? Commun Dis Intell 2003;27:537–540.

247.     Forrest JM, Burgess M, Donovan T. A resurgence of congenital rubella in Australia? Commun Dis Intell 2003;27:533–536.

248.     Francis BH, Thomas AK, McCarty CA. The impact of rubella immunization on the serological status of women of childbearing age: a retrospective longitudinal study in Melbourne, Australia. Am J Public Health 2003;93:1274–1276.

249.     Sathanandan D, Gupta L, Liu B, Rutherford A, Lane J. Factors associated with low immunity to rubella infection on antenatal screening. Aust N Z J Obstet Gynaecol 2005;45:435–438.

250.     Hunt JM, Lumley J. Top end rural and remote Indigenous women: an Australian population group vulnerable to rubella. Commun Dis Intell 2004;28:499–503.

251.     World Health Organization. Immunization surveillance, assessment and monitoring. Rubella and Congenital Rubella Syndrome (CRS). Statistics on rubella. 2006. Available from: www.who.int/immunization_monitoring/diseases/rubella/en/index.html Accessed on 23 November 2006.

252.     World Health Organization Regional Office for the Western Pacific. Report of the UNICEF/WHO workshop on the Expanded Programme on Immunization in the Pacific, Auckland, New Zealand, 8–12 March 2004. ((WP)ICP/EPI/5.2/001-A) Report series number: RS/2004/GE/03(NEZ). Manila, Philippines: World Health Organization, 2004. Available from: www.wpro.who.int/NR/rdonlyres/F8FCAC09-0232-4945-907B-0B24C98EB2D4/0/MTGRPT_PIC_JOINT2004.pdf Accessed on 23 November 2006.

253.     World Health Organization Regional Office for the Western Pacific. Western Pacific regional guidelines: introducing rubella vaccine. Draft of 25 March 2004. Available from: www.spc.int/phs/pphsn/Outbreak/Rubella/WPRO_Rubella_Guidelines_DRAFT-v1.pdf Accessed on 23 November 2006.

254.     Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006;43 Suppl 3:S123–S125.

255.     World Health Organization. Eliminating measles and rubella and preventing congenital rubella infection. WHO European Region strategic plan 2005–2010. Available from: www.euro.who.int/document/E87772.pdf Accessed on 23 November 2006.

256.     Dayan GH, Castillo-Solórzano C, Nava M, et al. Efforts at rubella elimination in the United States: the impact of hemispheric rubella control. Clin Infect Dis 2006;43 Suppl 3:S158–S163.

257.     Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec 2005;80:126–132.

258.     Global distribution of measles and rubella genotypes-update. Wkly Epidemiol Rec 2006;81:474–479.

259.     The fourth WHO Global Measles and Rubella Laboratory Network meeting, 28–30 August 2006, WHO, Geneva. Final summary and recommendations. Available from: www.who.int/immunization_monitoring/FinalSummaryMeaslesRubellaMeetingAug06.pdf Accessed on 23 November 2006.

260.     Icenogle JP, Frey TK, Abernathy E, et al. Genetic analysis of rubella viruses found in the United States between 1966 and 2004: evidence that indigenous rubella viruses have been eliminated. Clin Infect Dis 2006;43 Suppl 3:S133–S140.

261.     Quinn HE, McIntyre PB. Tetanus in the elderly – an important preventable disease in Australia. Vaccine 2007;25:1304–1309.

262.     Skowronski DM, Pielak K, Remple VP, et al. Adult tetanus, diphtheria and pertussis immunization: knowledge, beliefs, behavior and anticipated uptake. Vaccine 2004;23:353–361.

263.     Bovier PA, Chamot E, Bouvier Gallacchi M, Loutan L. Importance of patients' perceptions and general practitioners' recommendations in understanding missed opportunities for immunisations in Swiss adults. Vaccine 2001;19:4760–4767.

264.     Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984–2000. Epidemiol Infect 2003;130:71–77.

265.     Bowman C, Hearing S, Bewley J. Tetanus toxoid for adults. Lancet 1996;348:1664.

266.     Maple PA, Jones CS, Wall EC, et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2000;19:167–173.

267.     McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002;136:660–666.

268.     Yuan L, Lau W, Thipphawong J, et al. Diphtheria and tetanus immunity among blood donors in Toronto. CMAJ 1997;156:985–990.

269.     de Melker HE, van den Hof S, Berbers GA, Conyn-van Spaendonck MA. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003;21:716–720.

Top of page

270.     Turnbull F, Baker M, Tsang B, Jarman J. Epidemiology of tetanus in New Zealand reinforces value of vaccination. New Zealand Public Health Report 2001;8:57–60.

271.     Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance – United States, 1998–2000. MMWR Surveill Summ 2003;52(SS–3):1–8.

272.     Public Health Agency of Canada. Notifiable diseases on-line. Tetanus. Available from: dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/disease2/tetn_e.html Accessed on 22 September 2006.

273.     Health Protection Agency. Ongoing national outbreak of tetanus in injecting drug users. Commun Dis Rep CDR Wkly 2004;14(9):2-4. Available from: www.hpa.org.uk/cdr/archives/2004/cdr0904.pdf Accessed on 13 April 2007.

274.     Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis 1984;3:505–509.

275.     Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 2003;131:1085–1089.

276.     Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986;78:723–727.

277.     Brody MB, Moyer D. Varicella-zoster virus infection. The complex prevention-treatment picture. Postgrad Med 192;102(1):187–190.

278.     Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999;3:335–342.

279.     Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000;181:1897–1905.

280.     Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985;76:512–517.

281.     Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001;8:32–36.

282.     Forrest JM, Mego S, Burgess MA. Congenital and neonatal varicella in Australia. J Paediatr Child Health 2000;36:108–113.

283.     Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–2284.

284.     MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003;131:675–682.

285.     Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 2002;287:606–611.

286.     Hope-Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952;260:549–554.

287.     Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;125:651–669.

288.     Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002;360:678–682.

289.     Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500–2507.

290.     Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis 2005;191:2002–2007.

291.     Macartney K, McIntyre P. Universal varicella vaccination [letter]. Med J Aust 2005;183:278–279.

292.     Communicable Diseases Network Australia. A report from the Communicable Diseases Network Australia, 1 April to 30 June 2005. Commun Dis Intell 2005;29:315.

293.     Roche P. Surveillance plans for Australia. Presentation at NCIRS VZV Workshop, Sydney, 16–17 November 2006. Available from: www.ncirs.usyd.edu.au/newsevents/vzv_workshop_presentations_nov_06.doc Accessed on 8 March 2007.

294.     Communicable diseases surveillance. Additional reports. Childhood immunisation coverage. Commun Dis Intell 1998;22:233.

295.     Communicable diseases surveillance. Additional reports. Childhood immunisation coverage. Commun Dis Intell 2002;26:491.

296.     Lawrence GL, Hull BP, MacIntyre CR, McIntyre PB. Reasons for incomplete immunisation among Australian children. A national survey of parents. Aust Fam Physician 2004;33:568–571.

297.     Hull BP, McIntyre PB. Timeliness of childhood immunisation in Australia. Vaccine 2006;24:4403–4408.

298.     Hanna JN, Wakefield JE, Doolan CJ, Messner JL. Childhood immunisation: factors associated with failure to complete the recommended schedule by two years of age. Aust J Public Health 1994;18:15–21.

299.     Hull BP, McIntyre PB, Sayer GP. Factors associated with low uptake of measles and pertussis vaccines: an ecologic study based on the Australian Childhood Immunisation Register. Aust N Z J Public Health 2001;25:405–410.

Top of page

300.     Taylor A, Wilson D, Dal Grande E, Gill T. National influenza survey: a population survey of vaccination uptake in Australia. Adelaide: Centre for Population Studies in Epidemiology, Epidemiology Branch, South Australian Department of Human Services, 2000. Available from: dh.sa.gov.au/pehs/PROS/flu-vaccination-2000.pdf Accessed on 12 March 2007.

301.     Hull BP, McIntyre PB. What do we know about 7vPCV coverage in Aboriginal and Torres Strait Islander children? Commun Dis Intell 2004;28:238–243.

302.     Burgess MA, McIntyre PB. Vaccines: the new Australian best-practice schedule. Med J Aust 2004;180:494–496.

303.     World Health Organization Press Release WHO/71 (29 October 2000). Major milestone reached in global polio eradication: Western Pacific Region is certified polio-free. Commun Dis Intell 2000;24:304.

304.     New Zealand Ministry of Health. Institute of Environmental Science and Research. New Zealand Public Health Observatory. Available from: www.nzpho.org.nz/ Accessed on 8 November 2006.

305.     Centers for Disease Control and Prevention. Summary of notifiable diseases – United States, 2004. MMWR Morb Mortal Wkly Rep 2006;53:1–84. Available from: www.cdc.gov/mmwr/PDF/wk/mm5353.pdf Accessed on 8 November 2006.

306.     Health Canada. Population and Public Health Branch. Notifiable Diseases. Available from: dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_dis_e.html Accessed on 8 November 2006.

307.     Health Protection Agency. Infectious Diseases section. Available from: ttp://www.hpa.org.uk/infections/default.htm Accessed on 8 November 2006.

308.     Lawrence GL, MacIntyre CR, Hull BP, McIntyre PB. Effectiveness of the linkage of child care and maternity payments to childhood immunisation. Vaccine 2004;22:2345–2350.

309.     Australian Government Department of Health and Ageing. Review of the General Practice Immunisation Incentives (GPII) Scheme. Canberra: Australian Government Department of Health and Ageing, 2004. Available from: www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/DF7218195E74C315CA25719D00183387/$File/gpii_review_2004.pdf Accessed on 13 March 2007.

310.     Skull S. A review of national notifiable disease case definitions [report to Communicable Diseases Network Australia and New Zealand (CDNANZ)]. January 2001.

311.     O'Grady KA, Counahan M, Birbilis E, Tallis G, eds. Surveillance of notifiable infectious diseases Victoria, 2002. Melbourne: Communicable Diseases Section, Rural and Regional Health and Aged Care Services, Victorian Department of Human Services, 2003. Available from: www.health.vic.gov.au/ideas/downloads/annual_rpts/snid2002_complete.pdf Accessed on 22 February 2007.

312.     Guy RJ, Andrews RM, Kelly HA, et al. Mumps and rubella: a year of enhanced surveillance and laboratory testing. Epidemiol Infect 2004;132:391–398.

Document download

This publication is available as a downloadable document.

Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2003 to 2005(PDF 1622 KB)